



Only Anoro has positive head-to-head data vs. Spiolto



1.4x superior improvement in lung function vs Spiolto (180ml vs. 128ml change from baseline in trough FEV1 at week 8; 95% CI, 28, 77; p<0.001) [1]



2x the odds of achieving a clinically meaningful improvement† in lung function with Anoro vs. Spiolto (95% CI 1.34, 3.14; OR = 2.05, p<0.001) [1]



More patients prefer Ellipta vs. Respimat for ease of use (p<0.001) in patients declaring a preference [1]

Cardiovascular events, such as cardiac arrhythmias, may be seen after the administration of muscarinic receptor antagonists and sympathomimetic agents, including umeclidinium/vilanterol. Therefore, Anoro Ellipta should be used with caution in patients with severe cardiovascular disease. [7]

Due to antimuscarinic activity (i.e. a LAMA class effect), Anoro Ellipta and Spiriva should be used with caution in patients with urinary retention or narrow angle glaucoma. [7] [11]

At first ANORO showed superiority vs. Spiriva*** [3] [4]

Now ANORO shows superiority vs. Spiolto [1]

A new head-to-head, in-class comparison study across multiple endpoints has been published that demonstrates superiority of ANORO over Spiolto on lung function. [1]

References:

- [1] Feldman G.J et al. *Adv Ther* 2017; 34:doi 10.1007/s12325-017-0626-4
- [2] Calverley PM et al. *Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations. Int J COPD* 2016; 11 :381–390.
- [3] Maleki-Yazdi M et al. *Adv Ther* 2016; 33:2188–2199.
- [4] GSK Data on file: RF/UCV/0112/15.
- [5] Thomas M et al. *No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J* 2013; 22 :101–111.
- [6] O'Donnell DE, Laveneziana P. *Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev* 2006; 15: 61–67.
- [7] [Anoro Ellipta prescribing information](#)
- [8] *Spiolto Respimat Summary of Product Characteristics. Boehringer Ingelheim* 2017.
- [9] *Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: http://goldcopd.org. [Accessed August 2017]*
- [10] GSK Data on file: RF/UCV/0073/17
- [11] *Spiriva SmPC, 2015*

Adverse events should be reported. Reporting forms and information can be found at il.safety@gsk.com.
Adverse events should also be reported to GlaxoSmithKline at +9723 9297100.

Anoro and Ellipta are registered trademarks of the GlaxoSmithKline group of companies.

il/ucv/0011/18a

Get in touch

To discuss our products, supply, educational events or any other information please click on the link below.

[Contact us](#)

[Public site](#)
www.gsk.com

[Change country](#)
[Sitemap](#)
[Terms of use](#)
[Privacy Notice](#)